Canaccord Genuity Starts Obalon Therapeutics (OBLN) at Buy
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Canaccord Genuity initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $17.00.
Shares of Obalon Therapeutics closed at $13.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Genuity Upgrades Autodesk (ADSK) to Buy
- Broadcom (AVGO) PT Raised to $215 at Oppenheimer
- Finisar (FNSR) PT Raised to $44 at Needham & Company, Estimates Raised Sharply
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesCanaccord Genuity
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!